Technology evaluation: ISIS-113715, Isis.
G Liu - Current opinion in molecular therapeutics, 2004 - europepmc.org
G Liu
Current opinion in molecular therapeutics, 2004•europepmc.orgTechnology evaluation: ISIS-113715, Isis. - Abstract - Europe PMC Sign in | Create an account
https://orcid.org Europe PMC Menu About Tools Developers Help Contact us Helpdesk
Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus Search life-sciences
literature (Over 40 million articles, preprints and more) Search Advanced search Feedback This
website requires cookies, and the limited processing of your personal data in order to function.
By using the site you are agreeing to this as outlined in our privacy notice and cookie policy …
https://orcid.org Europe PMC Menu About Tools Developers Help Contact us Helpdesk
Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus Search life-sciences
literature (Over 40 million articles, preprints and more) Search Advanced search Feedback This
website requires cookies, and the limited processing of your personal data in order to function.
By using the site you are agreeing to this as outlined in our privacy notice and cookie policy …
Isis is developing ISIS-113715, an antisense inhibitor of the PTP1B gene, for the potential treatment of type 2 diabetes and obesity. ISIS-113715 is undergoing phase II clinical trials.
europepmc.org